MM-093: Completed Phase IIa enrollment

Merrimack completed enrollment in the double-blind, placebo-controlled, U.S. Phase IIa trial in 27 patients. MM-093 will be administered subcutaneously once-weekly for 12 weeks, with a follow-up of 6 ...